Skip Navigation

Japanese Journal of Clinical Oncology 2004 34(12):733-739; doi:10.1093/jjco/hyh135
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ishii, H.
Right arrow Articles by Yoshino, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ishii, H.
Right arrow Articles by Yoshino, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2004 Foundation for Promotion of Cancer Research

Extrahepatic Spread from Hepatocellular Carcinoma: Who are Candidates for Aggressive Anti-cancer Treatment?

Hiroshi Ishii1, Junji Furuse1, Taira Kinoshita2, Masaru Konishi2, Toshio Nakagohri2, Shinichiro Takahashi2, Naoto Gotohda2, Kouhei Nakachi1 and Masahiro Yoshino1

1 Division of Hepatobiliary and Pancreatic Medical Oncology and 2 Division of Upper Abdominal Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan

For reprints and all correspondence: Hiroshi Ishii, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. E-mail: hirishii{at}east.ncc.go.jp

Received August 4, 2004; accepted September 23, 2004

Background: There is no standard treatment for patients with extrahepatic spread from hepatocellular carcinoma. The aim of this retrospective study was to identify candidates for aggressive intervention or new drug trial among such patients.

Methods: Retrospective exploration was performed to extract a patient cohort step by step using univariate and multivariate analyses.

Results: There were 201 subjects from the past 12 years. The 1-, 3- and 5-year survival rates were 31.0, 9.2 and 4.5%, respectively. The upper limit of the 95% confidence interval of median survival time did not reach 3 months in patients with a performance status of 2 or worse, or with Child–Pugh grades B or C. After excluding those, univariate and multivariate analyses were performed in the remaining 124 subjects. Three independent prognostic factors—brain metastasis, number of metastatic tumors and primary tumor status—were identified. The final cohort was set at 121 after excluding three with brain metastasis. Among these 121, there were 11 with a solitary metastatic tumor and T1/2 primary tumor. In this subgroup, 10 underwent complete removal of the metastatic tumor, and the median survival time exceeded 5 years.

Conclusion: Candidates for anti-cancer treatment should meet the following requirements: a performance status of 0 or 1, a Child–Pugh grade A and no brain metastasis. Among these, challenging locoregional intervention was acceptable only for patients with solitary metastatic tumor and T1/2 primary tumor.

Key Words: liver neoplasm • metastasis • prognosis • surgery • ablation


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.